Fluorescence in Situ Hybridization Identifies More Aggressive Types of Primarily Noninvasive (Stage pTa) Bladder Cancer

No AccessJournal of UrologyClinical Urology: Original Article1 Jun 1997Fluorescence in Situ Hybridization Identifies More Aggressive Types of Primarily Noninvasive (Stage pTa) Bladder Cancer Armin Pycha, Christine Mian, Andrea Haitel, Johann Hofbauer, Helene Wiener, and Michael Marberger Armin PychaArmin Pycha , Christine MianChristine Mian , Andrea HaitelAndrea Haitel , Johann HofbauerJohann Hofbauer , Helene WienerHelene Wiener , and Michael MarbergerMichael Marberger View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)64690-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the genetic changes in cytological specimens of bladder cancer by fluorescence in situ hybridization, and related them to stage and grade of the tumor, ploidy, p53 and Ki-67 expression, and clinical outcome to determine a simple method to identify tumors with a poorer prognosis. Materials and Methods: Using fluorescence in situ hybridization the numerical aberrations of chromosomes 7, 9 and 17 in barbotages and imprints of 50 patients with transitional cell cancer of the bladder were determined. Of the patients 29 had a primary stage pTa tumor, while 21 with stage pT1 or greater disease formed the control group. Data were compared to ploidy status, and Ki-67 and p53 immunoreactivity. Results: Repeated monosomy 9 and haploid or diploid status on static ploidy determination were found in patients with primary stage pTa tumors without recurrence. Immunoreactivity of p53 was negative in all of these patients, while there was a low percentage of positive staining for Ki-67. Patients with recurrent and progressive disease had a high incidence of trisomy 7 and 17, aneuploid status and high positivity for both immunological markers. For chromosomes 7 and 17, and ploidy status bivariate analysis showed a significant difference. Conclusions: The evaluation of chromosomal aberrations in barbotage and imprint specimens clearly establishes a relationship between chromosomal defects and aggressiveness of the tumor. The majority of nonaggressive stage pTa transitional cell carcinomas can be distinguished from potentially lethal cases by fluorescence in situ hybridization at a diagnostic point when the grading is not yet prognostic. References 1 : Managing superficial bladder cancer: an overview. Urology1992; 40: 5. Google Scholar 2 : The relationship among multiple recurrences, progression and prognosis of patients with stages TA and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol.1995; 153: 1823. Link, Google Scholar 3 : Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res.1990; 50: 7081. Google Scholar 4 : A new approach in the diagnosis and follow-up of bladder cancer. FISH analysis of urine, bladder washings, and tumors. Cancer Genet. Cytogen.1993; 71: 105. Google Scholar 5 : Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res.1994; 54: 784. Medline, Google Scholar 6 : Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res.1993; 53: 5093. Medline, Google Scholar 7 : Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res.1991; 51: 3807. Medline, Google Scholar 8 : Bladder irrigation specimens assayed by fluorescence in situ hybridization to interphase nuclei. Cytometry1994; 17: 319. Crossref, Medline, Google Scholar 9 : Grading in superficial bladder cancer. (1) Morphological criteria. Brit. J. Urol.1988; 61: 129. Google Scholar 10 : p53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Brit. J. Urol.1993; 73: 533. Google Scholar 11 : Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Amer. J. Path.1994; 144: 756. Google Scholar 12 : The p53 tumor suppressor gene. Nature1991; 351: 453. Crossref, Medline, Google Scholar 13 : Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder. Brit. J. Urol.1994; 73: 522. Crossref, Medline, Google Scholar 14 : Cell cycling in bladder carcinoma determined by monoclonal antibody Ki67. Brit. J. Urol.1990; 66: 281. Google Scholar 15 : Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J. Urol.1992; 148: 1149. Link, Google Scholar 16 : UICC TNM Classification of Malignant Tumours. New York: Springer-Verlag1992. Google Scholar 17 : Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc. Nat. Acad. Sci.1986; 83: 2934. Google Scholar 18 : The use of Light Green and Orange II as quantitative protein stains, and their combination with the Feulgen method for simultaneous determination of protein and DNA. Histochemistry1984; 80: 49. Google Scholar 19 : . Philadelphia: J. B. Lippincott Co.1992: 1596. chapt. 35. Google Scholar 20 : Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene1993; 8: 1083. Medline, Google Scholar From the Departments of Urology and Clinical Pathology, University of Vienna, Vienna, Austria.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySAROSDY M, SCHELLHAMMER P, BOKINSKY G, KAHN P, CHAO R, YORE L, ZADRA J, BURZON D, OSHER G, BRIDGE J, ANDERSON S, JOHANSSON S, LIEBER M, SOLOWAY M and FLOM K (2018) Clinical Evaluation of a Multi-target Fluorescent in Situ Hybridization Assay for Detection of Bladder CancerJournal of Urology, VOL. 168, NO. 5, (1950-1954), Online publication date: 1-Nov-2002.HALLING K, KING W, SOKOLOVA I, KARNES R, MEYER R, POWELL E, SEBO T, CHEVILLE J, CLAYTON A, KRAJNIK K, EBERT T, NELSON R, BURKHARDT H, RAMAKUMAR S, STEWART C, PANKRATZ V, LIEBER M, BLUTE M, ZINCKE H, SEELIG S, JENKINS R and O'KANE D (2018) A Comparison of BTA Stat, Hemoglobin Dipstick, Telomerase and Vysis Urovysion Assays for the Detection of Urothelial Carcinoma in UrineJournal of Urology, VOL. 167, NO. 5, (2001-2006), Online publication date: 1-May-2002.HALLING K, KING W, SOKOLOVA I, MEYER R, BURKHARDT H, HALLING A, CHEVILLE J, SEBO T, RAMAKUMAR S, STEWART C, PANKRATZ S, O'KANE D, SEELIG S, LIEBER M and JENKINS R (2018) A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMAJournal of Urology, VOL. 164, NO. 5, (1768-1775), Online publication date: 1-Nov-2000.PYCHA A, MIAN C, POSCH B, HAITEL A, EL-BAZ M, GHONEIM M and MARBERGER M (2018) NUMERICAL ABERRATIONS OF CHROMOSOMES 7, 9 AND 17 IN SQUAMOUS CELL AND TRANSITIONAL CELL CANCER OF THE BLADDER: A COMPARATIVE STUDY PERFORMED BY FLUORESCENCE IN SITU HYBRIDIZATIONJournal of Urology, VOL. 160, NO. 3 Part 1, (737-740), Online publication date: 1-Sep-1998.Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H and Marberger M (2018) DOES TOPICAL INSTILLATION THERAPY INFLUENCE CHROMOSOMAL ABERRATIONS IN SUPERFICIAL BLADDER CANCER?Journal of Urology, VOL. 159, NO. 1, (265-269), Online publication date: 1-Jan-1998. Volume 157Issue 6June 1997Page: 2116-2119 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information Armin Pycha More articles by this author Christine Mian More articles by this author Andrea Haitel More articles by this author Johann Hofbauer More articles by this author Helene Wiener More articles by this author Michael Marberger More articles by this author Expand All Advertisement PDF downloadLoading ...